News | September 10, 2010

First Patient Supported with Transcatheter Right Heart VAD

September 10, 2010 – The first patient was successfully supported for six days by the Impella Right Peripheral (RP) ventricular assist device (VAD) at the Providence Heart and Lung Institute at St. Paul’s Hospital in Vancouver, British Columbia. This is the first use of the Impella RP.

The procedure was performed by Anson Cheung, M.D., of the Providence Heart and Lung Institute. The Impella RP is available to this institution under “special access” regulations in Canada.

“We are thrilled to be the first institution in the world to use the Impella RP for support in a patient,” said Anson Cheung, M.D., surgical director of heart transplantation for the Providence Heart and Lung Institute at St. Paul’s Hospital. “A common challenge for post-transplant patients with acute right heart failure is that they often have limited treatment options. The Impella RP represents a huge step forward in offering right side support using a minimally invasive platform. Our organization excels in offering revolutionary cardiac care for patients and the Impella RP allows us to improve the overall quality of life for patients suffering from heart failure."

The Impella RP is a percutaneous, catheter-based, axial flow pump. It is inserted via a single access vessel and does not require the patient’s chest to be opened. It is passed through the right ventricle and delivers greater than 4 liters of blood flow per minute from the lower right atrium to the pulmonary artery.

Patients with right ventricular dysfunction or right heart failure, lack blood flow from the right side of their hearts. The Impella RP is intended to provide the flow and pressure needed to compensate for right heart failure. Right heart failure can occur either as an isolated event or can be associated with left heart failure when the patient is suffering from biventricular failure.

Similar to the Impella 2.5 and 5.0, the Impella RP can be inserted in the catheterization lab or in the surgery suite. Cardiologists and surgeons will be able to treat right heart dysfunction without opening the patient’s chest or requiring another surgery. Some patient populations that could potentially benefit from percutaneous right-sided support are: post operative right ventricular dysfunction following transplant, Left VAD placement for heart surgery, cardiogenic shock, isolated right side failure from chronic heart disease, and elevated pulmonary artery blood pressure following pulmonary embolism.

The Impella RP is currently not available in the United States.

For more information: www.abiomed.com

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init